AlphaCrest Capital Management’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-14,154
Closed -$1.14M 339
2022
Q3
$1.14M Sell
14,154
-4,430
-24% -$375K 0.07% 524
2022
Q2
$1.39M Buy
18,584
+13,668
+278% +$1.25M 0.07% 508
2022
Q1
$629K Sell
4,916
-33,468
-87% -$3.66M 0.04% 786
2021
Q4
$5.15M Buy
38,384
+34,696
+941% +$4.99M 0.19% 89
2021
Q3
$504K Sell
3,688
-3,800
-51% -$479K 0.03% 902
2021
Q2
$799K Sell
7,488
-2,408
-24% -$231K 0.03% 766
2021
Q1
$889K Sell
9,896
-2,716
-22% -$255K 0.05% 551
2020
Q4
$1.17M Sell
12,612
-2,008
-14% -$179K 0.1% 268
2020
Q3
$1.51M Buy
14,620
+1,184
+9% +$124K 0.16% 148
2020
Q2
$1.36M Sell
13,436
-1,980
-13% -$177K 0.23% 93
2020
Q1
$1.04M Sell
15,416
-9,804
-39% -$610K 0.13% 263
2019
Q4
$1.38M Sell
25,220
-13,008
-34% -$617K 0.11% 212
2019
Q3
$1.43M Buy
38,228
+32,064
+520% +$1.25M 0.09% 375
2019
Q2
$231K Sell
6,164
-47,432
-88% -$1.49M 0.02% 939
2019
Q1
$1.6M Buy
+53,596
New +$1.88M 0.24% 83

Other funds holding DXCM

AlphaCrest Capital Management's DXCM Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of DexCom (DXCM) in Q4 2022, closing a stake of 14,154 shares — an estimated $1.14M sold.

AlphaCrest Capital Management first reported a position in DXCM in Q1 2019 and held it in 15 quarters. The position peaked at $5.15M in Q4 2021. 921 funds tracked by Wall St. Rank hold DXCM as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining DexCom position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 14,154 DexCom shares in Q4 2022, an estimated $1.14M.
  • AlphaCrest Capital Management first reported a position in DexCom in Q1 2019 and held it in 15 quarters.
  • AlphaCrest Capital Management's DexCom position peaked at $5.15M in Q4 2021.
  • 921 funds tracked by Wall St. Rank held DexCom as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.